Merck and Gilead among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
Company
Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc is a biopharmaceutical company. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. Gilead Sciences Inc offers products in HIV, Onocolgy, Liver Disease, Vekulaery and Other.
86 stories · page 4 of 5
US stocks end higher after stronger payrolls point to rate hike
US stocks ended the week at the top of their Friday session range after stronger-than-expected non-farm payrolls confirmed a Federal Reserve rate hike on March 15
Pharmaxis enters 2017 cashed up as shares strengthen
Pharmaxis is becoming a more enticing target for drug acquisition and partnerships.
US stocks recover from losses as analysts focus on surprise gasoline supply drop
US stocks recovered from intraday losses to end higher on Wednesday after analysts focused on a fall in gasoline inventories rather than a spike in oil supplies
Pharmaxis on track for multi-million euro milestone payment
The commencement of the trial will trigger a milestone payment.
AbbVie's revenue miss clouds strong Humira US sales
AbbVie Inc shares were lower on Friday after the pharma reported quarterly adjusted revenue that missed analysts' estimates as weaker-than-expected sales of its hepatitis C treatment and cancer therapy overshadowed strong US demand for its
Immuron watches several high-value NASH related deals
Microbiome company Immuron (ASX:IMC) is witnessing a series of high-value licensing merger & acquisition (LM&A) deals related to NASH (non-alcoholic steatohepatitis) assets.
Gilead order to pay US$2.54bn in royalties after losing patent battle
It is the biggest patent-infringement verdict in US history and, of course, the loser is appealing against it.
US stocks drop on election jitters
US stocks closed lower in a broad fall on Tuesday, led by dividend-paying sectors, as traders eyed a safer haven-inspired drop in Treasury bond yields as well as headlines on the looming presidential election a week away
Gilead Sciences to advance NASH treatment into phase III trials
Gilead announced phase II results for its selonsertib NASH treatment, which was tested in combination with simtuzumab, an antibody that contains Abzena’s technology
Gilead ends trial of ulcerative colitis treatment notes Abzena
The termination affects only one indication out of five currently being trialled by Gilead
Abzena's drug-boosting animal antibodies
Proactive Investors looks at Abzena, a biotech firm that engineers antibodies from animals in order to boost the effectiveness of cancer-fighting drugs.
Abzena's expanded offering plays well with customers
"Our increased capabilities and capacity are already resulting in an excellent response from customers,” said chief executive John Burt.
Gilead gets European Commission approval to market HIV drug
Truvada is first antiretroviral medicine licensed in Europe for pre-exposure prevention method
Medivation faces buyers’ scrum - report
A scrum to acquire US cancer drug company Medivation was emerging on Wednesday after reports that Merck, Pfizer and Gilead Sciences were among at least five pharmaceutical companies expressing an interest
Investments and investor services
Papers: Priceline CEO resigns following employee relationship investigation
Also featured: Amazon.com, Medivation, Gilead Sciences and Tobacco
Gilead's third TAF-Based HIV therapy approved by FDA
Gilead Sciences says the US Food and Drug Administration has approved Descovy, a fixed-dose combination for the treatment of HIV and "first new HIV treatment backbone approved in a decade"
Stocks find forward gear at last
The oil price (WTI) had its best day in seven years
Gilead Sciences can market HIV-1 drug in Europe
Gilead Sciences can now market its tablet for HIV-1 infection in Europe
Trending - Skechers, Gilead Sciences, Anavex Life Sciences, plus the top risers
A mention on Mad Money lights a fire under Skechers and Gilead Sciences.